HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Neurogene (NASDAQ:NGNE) and maintained a $55 price target.

May 03, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Neurogene with a $55 price target.
The reiteration of a Buy rating and maintenance of a $55 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100